Dennis Muhanguzi
ID: UNCST-2019-R001101
|
Accelerating Anti-Tick Vaccine Production Using Computational Approaches and Validation with An In-Vivo Model
REFNo: NS165ES
The specific objectives of this study will be to;
i.Create an open access queryable database of candidate anti-tick vaccine protein from I. scapularis proteome
ii.Identify single and chimeric antigenic anti-tick peptides basing on tick-specific amino acid sequences
iii.Evaluate the immunogenicity of five of the most promising antigenic single and chimeric anti-tick peptides in a laboratory animal [three months New Zealand rabbits] model
|
Uganda |
2021-06-10 |
2024-06-10 |
Natural Sciences |
|
Non-degree Award |
|
Jerome Kabakyenga Kahuma
ID: UNCST-2021-R013729
|
Smart discharges to improve post-discharge health outcomes in children below 6 months old
REFNo: SS855ES
To determine the effectiveness of a Smart Discharge program on post-discharge health seeking behavior and mortality among children under 6 months of age admitted with a proven or suspected infection.
|
Uganda |
2021-06-08 |
2024-06-08 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Musa Sekikubo
ID: UNCST-2021-R014010
|
A multi-Centre, randomised, placebo controlled, double-blind, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine (GBS-NN/NN2) in women who are pregnant and living with HIV and women who are pregnant and do not have HIV
REFNo: HS1390ES
Objectives
Primary Objectives:
Safety:
To evaluate the safety and tolerability of the GBS-NN/NN2 vaccine in women living with HIV and women without HIV and their newborn babies from vaccination up to delivery/birth.
Immunological:
To compare the transfer rate of vaccine- specific immunoglobulin G (IgG) antibody concentrations from the mother to the baby at birth in women living with HIV with the transfer rate in women without HIV. This endpoint will be used to determine the sample size calculation.
Secondary Objectives
Safety: The safety and tolerability of the GBS-NN/NN2 vaccine in the mother and baby over the first 6 months post-partum, as assessed at 6 months of age.
Immunological: The secondary immunological objectives are:
• To compare IgG antibody responses, specific to the GBS-NN/NN2 vaccine, induced by the first and second vaccine doses over time in pregnant women living with HIV and pregnant women without HIV.
• To evaluate the concentration of IgG antibodies specific for the GBS-NN/NN2 vaccine up to 6 months post-delivery in the mother and baby in women with and without HIV.
• To determine the concentrations of vaccine specific IgG to GBS-NN/NN2 in cord blood at delivery in babies born to women with and without HIV.
Exploratory Objectives
• To compare between groups the isotype composition of the vaccine specific antibodies; in particular IgG and IgA as well as their subclasses, i.e. IgG1-4, IgA1 and IgA2 in maternal and cord blood.
• To compare between groups the vaccine specific IgG antibodies to Rib, Alp1, Alp2 and AlpC, GBS-NN and GBS-NN2 in maternal and cord blood.
• To compare between groups the functional activity of vaccine specific antibodies from cord blood in an opsonophagocytic killing assay (OPkA) and other in vitro assays in selected samples.
|
Uganda |
2021-06-08 |
2024-06-08 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Flavia Matovu Kiweewa
ID: UNCST-2021-R013337
|
Using Recency Assays to estimate incident HIV infections among Adolescent Girls and Young Women in Hoima and Mityana/Mubende Districts, Uganda Version 2.0 dated 14 April 2021: Gilead Protocol Number :CO-US-985-6117(eStimating hIv incidEnce amoNg Agyw (SIENA) Study)
REFNo: HS1439ES
Primary Objective
i) To estimate the proportion of incident recent HIV infections among AGYWs aged 16-25 years in Hoima and Mityana/ Mubende districts, Uganda.
Secondary Objective
ii) To compare HIV incidence estimated using the Asanté™ HIV-1 Rapid Recency POC kit with that obtained using the Sedia™ HIV-1 LAg-Avidity EIA and the Abbott ARCHITECT HIV Ag/Ab Combo assays.
|
Uganda |
2021-06-08 |
2024-06-08 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Sifiso Lukhele Mbhekeni
ID:
|
GENOMIC EVIDENCE OF THE ROLE OF COMMUNICATION SIGNALS IN MEDIATING REPRODUCTIVE ISOLATION AT CONTACT ZONES
REFNo: NS117ES
1. Identify the threshold of variation in communication signals above which species boundaries are maintained.
2. Determine the importance of divergence time and time since secondary contact on levels of interbreeding.
|
South Africa |
2021-06-04 |
2024-06-04 |
Natural Sciences |
Non-Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|